Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
The accepted abstract is listed below and now available on the ASH conference website: https://hematology.org/Annual-Meeting/.
Poster Title: Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Session Title: Myeloproliferative Syndromes: Clinical: Poster II
Session Date & Time:
Abstract Number: 2950
Investor Event and Webcast Information
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We are currently advancing three investigational medicines in clinical development, along with multiple research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-initial-data-from-phase-2-pioneer-trial-of-avapritinib-in-patients-with-indolent-systemic-mastocytosis-at-61st-ash-annual-meeting-and-exposition-300952819.html
Investor Relations Contact, Kristin Hodous, 617-714-6674, email@example.com; Media Relations Contact, Andrew Law, 617-844-8205, firstname.lastname@example.org